new glp 1 agonist In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron Five Unexpected New Uses for

The suggested treatment algorithm of the ADA and EASD stratifies patients without pre-existing cardiovascular disease further

Based on the strength of the clinical data, we expect Wegovy to be added to formularies with utilization management restrictions for prior authorization to prevent off-label use, shorter initial approval periods (e.g., six months approved initially) to ensure efficacy, and quantity limits to reduce stockpiling and waste

However, as with injectable GLP-1s, cost may be a consideration in determining access to the Wegovy pill, particularly since many insurance plans dont cover obesity medications, Dushay says

It may provide an alternative option if approved